Connect with us

Technology

Senhwa’s CX-5461 Opens a New Frontier in Photoimmunotherapy; Multinational Study Published in Nucleic Acids Research

Published

3 months ago

on

TAIPEI and SAN DIEGO, Aug. 12, 2026 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492) today announced a significant research advance involving its investigational drug Pidnarulex (CX-5461). A multinational research team comprising investigators from Poland, Slovakia, France and Senhwa Biosciences in Taiwan found that, under specific cell-based experimental conditions, controlled light activation increased the cancer-cell-killing activity of CX-5461 by up to 96-fold and induced immunogenic cell death (ICD). The findings, published in the peer-reviewed journal Nucleic Acids Research, reveal that CX-5461 may have potential applications in photodynamic therapy and photoimmunotherapy in addition to its established research profile involving G-quadruplex (G4) targeting and DNA-damage-related mechanisms. The study opens a potential new development path for this clinical-stage asset.

Turning Photosensitivity into a Controlled Therapeutic Mechanism
Photosensitivity observed during the clinical development of CX-5461 has generally been viewed as a drug characteristic requiring risk management. In the new study, researchers reframed this property as a potentially controllable and spatially targeted therapeutic mechanism. By applying light of an appropriate wavelength to the tumor area, CX-5461 may be activated at the intended site, increasing local tumor-cell killing while limiting activity in non-illuminated tissue.

This light-switch concept could extend CX-5461 from a systemically administered anticancer agent into a photosensitizer with temporal and spatial control. The approach may warrant further investigation in tumors that are accessible to external light, endoscopy or fiber-optic delivery, including selected skin, oral and esophageal tumors.

Light Activation Triggers Tumor-Cell Killing and Immunogenic Cell Death
The study further showed that light-activated CX-5461 not only directly damaged cancer cells but also induced ICD. When cancer cells die through an immunogenic process, they release or expose danger-associated signals, including cell-surface calreticulin, extracellular ATP and high-mobility group box 1 (HMGB1). These signals can help dendritic cells recognize and take up tumor antigens, potentially initiating a T-cell-mediated antitumor immune response.

The therapeutic objective may therefore extend beyond destroying an illuminated local tumor. By making antigens from dying cancer cells more visible to the immune system, the treatment could provide a biological basis for using localized therapy to stimulate a broader antitumor immune response.

Preclinical Findings Support an In Situ Cancer Vaccine Concept
In preclinical mouse studies, animals whose tumors regressed after treatment with CX-5461 and light exposure showed suppressed tumor growth when subsequently challenged with the same cancer cells. The observation suggests that treatment may establish tumor-specific immune memory and supports further investigation of an in situ cancer vaccine concept. Under this approach, the patient’s own tumor could serve as the source of tumor antigens, allowing an immune response to be initiated at the treatment site without the need to manufacture an external vaccine in advance.

If validated through additional studies, this mechanism could also be explored in combination with immune checkpoint inhibitors targeting PD-1 or PD-L1, with the goal of broadening or prolonging antitumor immune activity. These findings are preclinical and require confirmation in additional animal studies and human clinical trials.

Expanding the Potential Value of an Existing Clinical-Stage Asset
In drug development, a molecule can gain a second life when its existing properties and mechanisms are understood in a new way. CX-5461 has already generated a body of development data across chemistry, manufacturing and controls, toxicology, pharmacology and human clinical safety. The new research reframes photosensitivity as a potentially useful therapeutic mechanism and extends the molecule’s research potential beyond G4 targeting and DNA-damage response into photodynamic therapy, photoimmunotherapy and immune-combination strategies.

Compared with developing an entirely new molecule from the outset, identifying a new mechanism and potential indications for an existing clinical-stage asset may support development continuity and broaden its potential product lifecycle, subject to successful preclinical, regulatory and clinical evaluation.

Next Steps
Senhwa views these findings as an important starting point for repositioning the value of CX-5461. Based on further validation, the Company plans to evaluate suitable tumor types, dosing and illumination conditions, light-delivery technologies and potential combination strategies. Senhwa will also seek multinational academic and industry collaborations to support the clinical translation of this photoimmunotherapy approach.

Additional preclinical and regulatory work will be required before clinical development can proceed. The safety and efficacy of CX-5461 as a photodynamic or photoimmunotherapy treatment have not been established in human clinical trials, and CX-5461 has not been approved for commercial use in these applications.

Please find more details via linkage below:
https://academic.oup.com/nar/article/54/15/gkag777/8758773

About Senhwa Biosciences
Senhwa Biosciences, Inc. is a Taiwan-based biotechnology company developing novel oncology therapeutics for cancers with significant unmet medical needs. Its pipeline includes CX-5461 and CX-4945, which are being evaluated in solid tumors and hematologic malignancies through international clinical and research collaborations. For more information, visit https://www.senhwabio.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/senhwas-cx-5461-opens-a-new-frontier-in-photoimmunotherapy-multinational-study-published-in-nucleic-acids-research-302849454.html

SOURCE SENHWA BIOSCIENCES, INC.

Related Topics:
Continue Reading

Technology

Innovative Immunology Biotech Windward Bio Lists on Nasdaq

Published

59 minutes ago

on

November 14, 2026

By

SHANGHAI, Nov. 14, 2026 /PRNewswire/ — Windward Bio, a portfolio company of Qiming Venture Partners and a clinical-stage biotechnology company, successfully listed on Nasdaq on November 13, 2026. Windward Bio (Nasdaq: WWB) priced its IPO at $17.00 per share. Its shares closed at $28.50 on the first trading day, up 68% from the IPO price, giving the company a market capitalization of approximately $1.69 billion. This is Qiming Venture Partners’ 11th IPO in 2026.

Qiming Venture Partners invested in Windward Bio’s inaugural Series A financing in 2025 and continued to support the company in its Series B financing in 2026. Qiming also participated in this IPO financing round.

Windward Bio was founded in 2024 with a mission to transform the treatment paradigm for patients living with chronic inflammatory diseases through the development of differentiated biologic therapies targeting clinically validated disease pathways. Led by a team with extensive expertise across discovery, development, and commercialization, Windward Bio is advancing a pipeline of ultra-long-acting antibody medicines to improve clinical outcomes, reduce treatment burden and expand treatment options for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis.

Windward Bio’s lead program, WIN378, is a potentially novel anti-TSLP monoclonal antibody engineered for improved potency and extended half-life. WIN378 is currently being evaluated in POLARIS-1, a Phase 2/3 study in severe uncontrolled asthma, and SIRIUS, a Phase 2 study in COPD. The company’s pipeline also includes WIN027, a clinical-stage, long-acting bispecific antibody targeting TSLP and IL-13 with potential applications across multiple inflammatory and immunological diseases. Windward Bio holds exclusive global rights (excluding Greater China and certain Asian countries) to WIN378 through a licensing agreement with Kelun-Biotech and Harbour BioMed, and has separately licensed WIN027 from Qyuns Therapeutics.

“Qiming Venture Partners invests in differentiated, globally competitive biotech innovation designed to address significant unmet needs for patients, and Windward Bio exemplifies this approach. We believe novel, long-acting biologics will reshape the treatment of severe chronic respiratory and skin diseases, and that WIN378 and WIN027 have the potential to expand and meaningfully improve the treatment options available to patients. In the hands of Luca and his team, with their expertise and proven track record, Windward is well-positioned to deliver on this potential, and we look forward to supporting the company through its next phase of growth,” said Alexander Sinclair Wilson, Principal at Qiming Venture Partners.

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 630 fast-growing and innovative companies. Over 290 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 110 portfolio companies that have achieved unicorn or super unicorn status.

Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren Technology, Z.AI, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine, AusperBio, Yuanxin Technology, Medilink Therapeutics, LaNova Medicines, StepFun, among many others.

 

View original content:https://www.prnewswire.com/news-releases/innovative-immunology-biotech-windward-bio-lists-on-nasdaq-302939481.html

SOURCE Qiming Venture Partners

Continue Reading

Technology

WeFetch AI Corp. Is the New Name of GreenCore Solutions Corp.

Published

2 hours ago

on

November 14, 2026

By

gtinfetch.ai, WeFetch.ai’s lead product, removes the guess from artificial intelligence (AI) shopping: the right barcode, and signed proof of it.

VANCOUVER, BC and LONDON, Nov. 13, 2026 /PRNewswire/ — WeFetch AI Corp., the artificial intelligence (AI) shopping company formerly named GreenCore Solutions Corp., has completed its change of name. The Registrar of Companies for British Columbia issued the Certificate of Change of Name on November 13, 2026.

One Answer for Every Barcode

An AI agent picks a product in words. The same words can match a dozen barcodes: the right brand in the wrong size, last year’s pack, a look-alike from another maker. When the agent guesses, the shopper gets the wrong product, the brand loses a sale it had already won, and the retailer pays for the return.

The Company’s lead product, gtinfetch.ai, removes the guess. It answers for 84,810,515 barcodes from 376,271 makers across 3,520,471 points of sale. An AI agent sends a barcode and gets a firm answer: verified, not verified or unknown, with the sources behind it.

Who it matters to:

The shopper gets the product they asked for.The brand keeps the sale the AI already gave it.The retailer does not pay for a wrong order.

A Signed Receipt of Every Check

When an AI agent buys on a shopper’s behalf, someone has to be able to show it bought the right product. Today nobody can: the agent’s choice leaves no record. gtinfetch.ai gives the agent a signed receipt of the check, written at rco.wefetch.ai and open to public verification. The retailer, the brand and the auditor can each see what was checked, when, and what the answer was. The mark is “Barcode verified”.

Three Regions, One Record

The full record now answers from France, Singapore and the United States. Every barcode also has its own free public page at gtinfetch.ai. The three regions are where AI shopping starts. Singapore has the highest consumer use of generative AI in Asia, at 64.3% of working-age people. France stands at 49.6% and the United States at 33.0%, against 18.8% worldwide. (Source: Microsoft AI Diffusion Report, Q2 2026.) They are also the home markets of the AI that shoppers ask: ChatGPT and Claude in the United States, Mistral in France, and Singapore among the top countries in the world for Claude use per head. (Source: Anthropic Economic Index.)

What we built

WeFetch.ai, the barcode fetch system for AI agents. It answers for 84 million products in 70 countries, with 3.5 million points of sale on its own record, and includes:

triggerfetch for brands;shopfetch for shoppers;matchfetch for AI agents;gtinfetch, the record itself.

It is AI native, and works with ChatGPT, Claude, Gemini, Grok, Mistral, Perplexity and Muse. Every answer is signed.

“Words were the first generation of AI answers. Barcodes are agentic commerce,” said Matthew Keddy, Chief Executive Officer of WeFetch AI Corp. “Every AI agent that moves from search results to shopping needs barcode precision. wefetch has it, signed, in three regions.”

The market: Gartner forecasts $2.7 trillion in AI spending in 2026. McKinsey projects that AI agents will orchestrate $3 trillion to $5 trillion in global commerce by 2030, up to $1 trillion of it in US retail. Every one of those AI agent purchases needs the right barcode.

About WeFetch AI Corp.

WeFetch AI Corp. develops AI software products for AI shopping, retail, grocery and fast-moving consumer goods (FMCG). Its lead product, gtinfetch.ai, is the AI agentic shopping barcode engine: 84 million barcodes, answered for the agents of seven AI labs. WeFetch is headquartered in Vancouver, Canada, with sales offices in London, UK. Please visit: wefetch.ai

View original content:https://www.prnewswire.com/news-releases/wefetch-ai-corp-is-the-new-name-of-greencore-solutions-corp-302939459.html

SOURCE Greencore Solutions Corp.

Continue Reading

Technology

/C O R R E C T I O N – BTQ Technologies Corp./

Published

3 hours ago

on

November 14, 2026

By

In the news release, BTQ Technologies to Host Live Webinar on Q3 2026 Financial Results and General Corporate Update, issued Nov. 13, 2026 by BTQ Technologies Corp. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows:

BTQ Technologies to Host Live Webinar on Q3 2026 Financial Results and General Corporate Update

VANCOUVER, BC, Nov. 13, 2026 /PRNewswire/ — BTQ Technologies Corp. (“BTQ” or the “Company”) (Nasdaq: BTQ) (CBOE CA: BTQ),  a global technology company building the trust infrastructure for the quantum era, is pleased to announce that it will hold a shareholder call on Friday, November 17, 2026, at 11:00 a.m. EST to discuss its quarterly financial results and provide a general corporate update. The call will follow the release of the Company’s Q3 2026 financial statements, which will be issued after market close on Monday, November 16, 2026.

IMPORTANT – To register for the webcast see below:

When: November 17, 2026
Time: 11:00 AM Eastern Time
Topic: BTQ Technologies Shareholder Call to Discuss Q3 2026 Financial Results and Corporate Update

Register in advance for this webinar:
https://us06web.zoom.us/webinar/register/WN_n6WGI3lERpCZcA63pWQWVQ 

After registering, you will receive a confirmation email containing information about joining the webinar.

About BTQ
BTQ Technologies Corp. (Nasdaq: BTQ | Cboe CA: BTQ) is a quantum technology company focused on accelerating the transition from classical networks to the quantum internet. Backed by a broad patent portfolio and deep technical expertise, BTQ is developing a full-stack, neutral-atom quantum computing platform spanning hardware, middleware, and post-quantum security solutions for finance, telecommunications, logistics, life sciences, and defense.

Connect with BTQ: Website | LinkedIn | X/Twitter

ON BEHALF OF THE BOARD OF DIRECTORS
Olivier Roussy Newton
CEO, Chairman

Neither Cboe Canada nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Information

Certain statements herein contain forward-looking statements and forward-looking information within the meaning of applicable securities laws. Such forward-looking statements or information include but are not limited to statements or information with respect to the business plans of the Company, including with respect to its research partnerships, and anticipated markets in which the Company may be listing its common shares. Forward-looking statements or information often can be identified by the use of words such as “anticipate”, “intend”, “expect”, “plan” or “may” and the variations of these words are intended to identify forward-looking statements and information.

The Company has made numerous assumptions including among other things, assumptions about general business and economic conditions, the development of post-quantum algorithms and quantum vulnerabilities, and the quantum computing industry generally. The foregoing list of assumptions is not exhaustive.

Although management of the Company believes that the assumptions made and the expectations represented by such statements or information are reasonable, there can be no assurance that forward-looking statements or information herein will prove to be accurate. Forward-looking statements and information are based on assumptions and involve known and unknown risks which may cause actual results to be materially different from any future results, expressed or implied, by such forward-looking statements or information. These factors include risks relating to: the availability of financing for the Company; business and economic conditions in the post-quantum and encryption computing industries generally; the speculative nature of the Company’s research and development programs; the supply and demand for labour and technological post-quantum and encryption technology; unanticipated events related to regulatory and licensing matters and environmental matters; changes in general economic conditions or conditions in the financial markets; changes in laws (including regulations respecting blockchains); risks related to the direct and indirect impact of COVID-19 including, but not limited to, its impact on general economic conditions, the ability to obtain financing as required, and causing potential delays to research and development activities; and other risk factors as detailed from time to time. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

Correction: An earlier version of this release incorrectly [describe the update briefly].

View original content to download multimedia:https://www.prnewswire.com/news-releases/btq-technologies-to-host-live-webinar-on-q3-2026-financial-results-and-general-corporate-update-302939440.html

SOURCE BTQ Technologies Corp.

Continue Reading

Trending